- MannKind (NASDAQ:MNKD): Q4 Non-GAAP EPS of -$0.06 misses by $0.01; GAAP EPS of -$0.11 misses by $0.07.
- Revenue of $18.44M (+15.3% Y/Y) beats by $2.28M.
- “Our fourth quarter produced exceptional results, with $10.1 million in Afrezza net revenue and positive clinical data for Tyvaso DPI from the BREEZE study conducted by United Therapeutics,” said Michael Castagna, Chief Executive Officer of MannKind Corporation. “UT also announced their plan to submit a new drug application for Tyvaso DPI to the FDA in April 2021. During the fourth quarter, we solidified our new direction with the acquisition of QrumPharma, which added a nebulized version of clofazimine to our pipeline of therapies for orphan lung diseases, and we entered into a collaboration agreement with Vertice for the co-promotion of Thyquidity, which is indicated for hyperthyroidism and is expected to expand our reach into endocrine diseases.”
- Shares +2% PM.
- Press Release